Search

IntroductionAlthough the etiology of depression is incredibly complex, the narrative that it is caused by a simple “chemical imbalance” persists in lay settings. We sought to understand where people are exposed to this explanation (i.e., the “source”), and the relative influence of each source.MethodsA total of 1,219 college students were asked where they had heard of the chemical imbalance explanation and how much they believed this to be true. Independent raters coded open-ended responses and we used self-report measures to capture chemical imbalance belief endorsement.ResultsThe most common sources of exposure to this explanation were the classroom, the Internet/media, other people (e.g., friends), and healthcare providers. In a regression analysis, only learning about the chemical imbalance explanation from healthcare providers uniquely predicted the adoption of the chemical imbalance belief. The correlation held even after controlling for depression symptoms, a family history of depression, and having had a diagnosis or treatment of mental health disorder (all of which also uniquely predicted chemical imbalance belief endorsement).DiscussionThese results suggest that healthcare providers play an important role in the dissemination of the chemical imbalance message, which is an oversimplified, scientifically controversial, and potentially treatment-interfering narrative. Interventions directed at healthcare providers may help them engage with more accurate messages.

We introduce two water-soluble excited state intramolecular proton transfer (ESIPT) based fluorescent turn-on probes responding to inorganic polyphosphates. These ESIPT probes enable specific detection of short-chain inorganic polyphosphates over a range of different condensed phosphates. The probes are weakly emissive in their off-state due to the blocking of ESIPT by Cu 2+ coordination. Removal of the copper ion through decomplexation by the analyte accesses the on-state. The probes detect polyphosphates over other biologically occurring phosphates, pyrophosphate, and nucleotides such as ATP, ADP, GTP. An optimal fluorescence response is observed with the short-chain polyphosphate polyP 8 . Furthermore, the probe shows selectivity towards linear polyphosphates over cyclic metaphosphates. The rapid 'turn-off-turn-on' fluorescence responses upon consecutive addition of Cu 2+ and polyP 8 are reversible, further highlighting sensor performance in an aqueous environment. One of the sensors is then used to monitor polyP digestion by an exopolyphosphatase (PPX).

Introduction: Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disease with no known cure, limited treatment options with minimal benefits, and significant unmet need for disease modifying therapies., Aims: This study investigated memantine's impact on ALS progression, with an additional focus on the effects of memantine on cognitive and behavioral changes associated with the disease., Methods: A randomized, double-blind, placebo-controlled clinical trial was conducted from December 2018 to September 2020. ALS patients were enrolled in-person and remotely across 13 sites in the United States. Participants were randomized to memantine (20 mg twice daily) or placebo in a 2:1 ratio and completed 36 weeks of treatment. The primary outcome of disease progression was assessed by the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R), and blood was collected for biomarker analysis., Results: Of the 99 participants enrolled in the study, 89 were randomized to memantine or placebo (ages 24-83 years, male-to-female ratio ~3:2). Fifty-two participants completed the study treatment with no significant differences in disease progression, biomarker changes (including neurofilament light chain [NfL]), or neuropsychiatric testing noted between the groups. Initial NfL values correlated with the rate of ALSFRS-R decline., Discussion: In this study, memantine did not impact ALS disease progression or neuropsychiatric symptoms. Trials with remote enrollment may help trial participation and success., (© 2024 The Author(s). Muscle & Nerve published by Wiley Periodicals LLC.)